{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:06:59Z","timestamp":1790168819896,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007113","name":"Arak University of Medical Sciences","doi-asserted-by":"publisher","award":["7701"],"award-info":[{"award-number":["7701"]}],"id":[{"id":"10.13039\/501100007113","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007113","name":"Arak University of Medical Sciences","doi-asserted-by":"publisher","award":["7701"],"award-info":[{"award-number":["7701"]}],"id":[{"id":"10.13039\/501100007113","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12824-5","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:40:11Z","timestamp":1790167211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming ABT-737 resistance in triple-negative breast cancer: C-phycocyanin-mediated myeloid cell leukemia-1 downregulation enhances apoptotic sensitivity"],"prefix":"10.1007","volume":"53","author":[{"given":"Shayesteh","family":"Khishavand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-8160","authenticated-orcid":false,"given":"Hadi","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"3","key":"12824_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12824_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.37349\/etat.2024.00215","volume":"5","author":"P De Santis","year":"2024","unstructured":"De Santis P et al (2024) Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response. Explor Target Antitumor Ther 5(1):232\u2013250","journal-title":"Explor Target Antitumor Ther"},{"key":"12824_CR3","doi-asserted-by":"crossref","unstructured":"Sriramulu S et al (2024) Present and Future of Immunotherapy for Triple-Negative Breast Cancer. Cancers (Basel) 16(19)","DOI":"10.3390\/cancers16193250"},{"key":"12824_CR4","first-page":"523","volume":"17","author":"A Agelidis","year":"2025","unstructured":"Agelidis A, Ter-Zakarian A, Jaloudi M (2025) Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond. Breast Cancer (Dove Med Press) 17:523\u2013529","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"12824_CR5","doi-asserted-by":"publisher","first-page":"1405491","DOI":"10.3389\/fonc.2024.1405491","volume":"14","author":"N Xiong","year":"2024","unstructured":"Xiong N, Wu H, Yu Z (2024) Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol 14:1405491","journal-title":"Front Oncol"},{"issue":"22","key":"12824_CR6","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P et al (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379(22):2108\u20132121","journal-title":"N Engl J Med"},{"issue":"5","key":"12824_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A et al (2018) Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 24(5):628\u2013637","journal-title":"Nat Med"},{"issue":"10265","key":"12824_CR8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817\u20131828","journal-title":"Lancet"},{"issue":"6","key":"12824_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M et al (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 377(6):523\u2013533","journal-title":"N Engl J Med"},{"key":"12824_CR10","doi-asserted-by":"crossref","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A (2019) Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells 8(9)","DOI":"10.3390\/cells8090957"},{"issue":"7","key":"12824_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS (2020) Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 17(7):395\u2013417","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"12824_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE et al (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15(1):49\u201363","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"12824_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K (2019) Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 20(3):175\u2013193","journal-title":"Nat Rev Mol Cell Biol"},{"key":"12824_CR14","doi-asserted-by":"crossref","unstructured":"Mukherjee N, Sheetz J, Shellman YG (2025) Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies. Int J Mol Sci 26(20)","DOI":"10.3390\/ijms26209859"},{"issue":"10","key":"12824_CR15","doi-asserted-by":"publisher","first-page":"113176","DOI":"10.1016\/j.celrep.2023.113176","volume":"42","author":"U Adhikary","year":"2023","unstructured":"Adhikary U et al (2023) Targeting MCL-1 triggers DNA damage and an anti-proliferative response independent from apoptosis induction. Cell Rep 42(10):113176","journal-title":"Cell Rep"},{"issue":"8","key":"12824_CR16","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1021\/acs.jmedchem.3c01998","volume":"67","author":"H Deng","year":"2024","unstructured":"Deng H et al (2024) Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions. J Med Chem 67(8):5963\u20135998","journal-title":"J Med Chem"},{"key":"12824_CR17","doi-asserted-by":"publisher","first-page":"118586","DOI":"10.1016\/j.biopha.2025.118586","volume":"192","author":"J Yu","year":"2025","unstructured":"Yu J et al (2025) Advances about the study of phycocyanin in the treatment of breast cancer: A review. Biomed Pharmacother 192:118586","journal-title":"Biomed Pharmacother"},{"key":"12824_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12935-018-0511-5","volume":"18","author":"L Jiang","year":"2018","unstructured":"Jiang L et al (2018) C-Phycocyanin exerts anti-cancer effects via the MAPK signaling pathway in MDA-MB-231 cells. Cancer Cell Int 18:12","journal-title":"Cancer Cell Int"},{"issue":"1\u20132","key":"12824_CR19","first-page":"35","volume":"32","author":"KJ Chavez","year":"2010","unstructured":"Chavez KJ, Garimella SV, Lipkowitz S (2010) Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 32(1\u20132):35\u201348","journal-title":"Breast Dis"},{"issue":"12","key":"12824_CR20","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.31557\/APJCP.2021.22.12.3993","volume":"22","author":"R Amini","year":"2021","unstructured":"Amini R, Karami H, Bayat M (2021) Combination Therapy with PIK3R3-siRNA and EGFR-TKI Erlotinib Synergistically Suppresses Glioblastoma Cell Growth In Vitro. Asian Pac J Cancer Prev 22(12):3993\u20134000","journal-title":"Asian Pac J Cancer Prev"},{"issue":"8","key":"12824_CR21","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.31557\/APJCP.2023.24.8.2705","volume":"24","author":"F Shahabi Nejad","year":"2023","unstructured":"Shahabi Nejad F, Karami H, Darvish M (2023) Triggering of Endoplasmic Reticulum Stress by Tannic Acid Inhibits the Proliferation and Migration of Colorectal Cancer Cells. Asian Pac J Cancer Prev 24(8):2705\u20132711","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"12824_CR22","first-page":"121","volume":"26","author":"Y Abbasi","year":"2024","unstructured":"Abbasi Y et al (2024) Formononetin and Dihydroartemisinin Act Synergistically to Induce Apoptosis in Human Acute Myeloid Leukemia Cell Lines. Cell J 26(2):121\u2013129","journal-title":"Cell J"},{"key":"12824_CR23","doi-asserted-by":"crossref","unstructured":"Naghashpour M et al (2023) Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells. Med (Kaunas) 59(2)","DOI":"10.3390\/medicina59020286"},{"issue":"20","key":"12824_CR24","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938\u20131948","journal-title":"N Engl J Med"},{"issue":"1","key":"12824_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s11658-025-00789-5","volume":"30","author":"Y Liu","year":"2025","unstructured":"Liu Y et al (2025) Programmed cell death in triple-negative breast cancer. Cell Mol Biol Lett 30(1):111","journal-title":"Cell Mol Biol Lett"},{"key":"12824_CR26","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1186\/s12885-015-1784-x","volume":"15","author":"M Ravi","year":"2015","unstructured":"Ravi M et al (2015) Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells. BMC Cancer 15:768","journal-title":"BMC Cancer"},{"issue":"7042","key":"12824_CR27","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677\u2013681","journal-title":"Nature"},{"issue":"5","key":"12824_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft MF et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell 10(5):389\u2013399","journal-title":"Cancer Cell"},{"issue":"1","key":"12824_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.canlet.2011.05.011","volume":"309","author":"L Zheng","year":"2011","unstructured":"Zheng L et al (2011) GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett 309(1):27\u201336","journal-title":"Cancer Lett"},{"issue":"6","key":"12824_CR30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1667\/RR13856.1","volume":"182","author":"H Wu","year":"2014","unstructured":"Wu H et al (2014) Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Radiat Res 182(6):618\u2013625","journal-title":"Radiat Res"},{"issue":"9","key":"12824_CR31","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1038\/s41418-021-00773-4","volume":"28","author":"KJ Campbell","year":"2021","unstructured":"Campbell KJ et al (2021) Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function. Cell Death Differ 28(9):2589\u20132600","journal-title":"Cell Death Differ"},{"issue":"5","key":"12824_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M et al (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10(5):375\u2013388","journal-title":"Cancer Cell"},{"issue":"12","key":"12824_CR33","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2174\/1389200220666191127110857","volume":"20","author":"SM Bannu","year":"2019","unstructured":"Bannu SM et al (2019) Potential Therapeutic Applications of C-Phycocyanin. Curr Drug Metab 20(12):967\u2013976","journal-title":"Curr Drug Metab"},{"issue":"12","key":"12824_CR34","doi-asserted-by":"publisher","first-page":"109725","DOI":"10.1016\/j.celrep.2021.109725","volume":"36","author":"F Simeoni","year":"2021","unstructured":"Simeoni F et al (2021) Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia. Cell Rep 36(12):109725","journal-title":"Cell Rep"},{"issue":"1","key":"12824_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41388-025-03634-3","volume":"45","author":"DJ Wisniewski","year":"2026","unstructured":"Wisniewski DJ et al (2026) EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition. Oncogene 45(1):15\u201325","journal-title":"Oncogene"},{"issue":"9","key":"12824_CR36","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/sj.bjc.6605335","volume":"101","author":"LY Lim","year":"2009","unstructured":"Lim LY et al (2009) Mutant p53 mediates survival of breast cancer cells. Br J Cancer 101(9):1606\u20131612","journal-title":"Br J Cancer"},{"issue":"6","key":"12824_CR37","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s43440-025-00780-z","volume":"77","author":"A Beberok","year":"2025","unstructured":"Beberok A et al (2025) MIM1 - a selective Mcl-1 protein inhibitor augments the proapoptotic activity of moxifloxacin toward MDA-MB-231 triple-negative breast cancer cells - a preliminary in vitro study. Pharmacol Rep 77(6):1703\u20131715","journal-title":"Pharmacol Rep"},{"issue":"9","key":"12824_CR38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41419-022-05214-9","volume":"13","author":"TL Bonneaud","year":"2022","unstructured":"Bonneaud TL et al (2022) Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties. Cell Death Dis 13(9):787","journal-title":"Cell Death Dis"},{"issue":"1","key":"12824_CR39","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s11033-024-09675-3","volume":"51","author":"A Motamedzadeh","year":"2024","unstructured":"Motamedzadeh A et al (2024) Therapeutic potential of Phycocyanin in gastrointestinal cancers and related disorders. Mol Biol Rep 51(1):741","journal-title":"Mol Biol Rep"},{"issue":"1","key":"12824_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","volume":"184","author":"I Vermes","year":"1995","unstructured":"Vermes I et al (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184(1):39\u201351","journal-title":"J Immunol Methods"},{"key":"12824_CR41","doi-asserted-by":"publisher","first-page":"34564","DOI":"10.1038\/srep34564","volume":"6","author":"G Liao","year":"2016","unstructured":"Liao G et al (2016) Phycocyanin Inhibits Tumorigenic Potential of Pancreatic Cancer Cells: Role of Apoptosis and Autophagy. Sci Rep 6:34564","journal-title":"Sci Rep"},{"issue":"3","key":"12824_CR42","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/bjc.2011.242","volume":"105","author":"S Pervin","year":"2011","unstructured":"Pervin S et al (2011) Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells. Br J Cancer 105(3):428\u2013437","journal-title":"Br J Cancer"},{"issue":"3","key":"12824_CR43","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/cdd.2008.137","volume":"16","author":"M Vogler","year":"2009","unstructured":"Vogler M et al (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16(3):360\u2013367","journal-title":"Cell Death Differ"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12824-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12824-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12824-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:40:14Z","timestamp":1790167214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12824-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12824"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12824-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"7 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants or animal experimentation. The research utilized the commercially available human MDA-MB-468 cell line. All experimental protocols were conducted in accordance with relevant institutional guidelines and regulations. The study design and ethical considerations were reviewed and approved by the Ethics Committee of AUMS (Approval Code: IR.ARAKMU.REC.1404.116).","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1614"}}